Long-term Kesimpta Use Not Seen in Trial to Depress Antibody Levels

Long-term Kesimpta Use Not Seen in Trial to Depress Antibody Levels

297465

Long-term Kesimpta Use Not Seen in Trial to Depress Antibody Levels

Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with a favorable safety profile for people living with [relapsing MS],” Marcia Kayath, global head medical affairs at Novartis Pharmaceuticals, which markets Kesimpta, said in a press release.…

You must be logged in to read/download the full post.